Status:
COMPLETED
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Radiological Society of North America
Conditions:
Ovarian Carcinoma
Eligibility:
FEMALE
18+ years
Brief Summary
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether th...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility and utility of 68Ga-PSMA PET imaging patients with ovarian cancer. II. Determine detection sensitivity for nodal metastases for PSMA PET stratifie...
Eligibility Criteria
Inclusion
- Patients with one of the following, identified on prior imaging (CT, MRI or Ultrasound):
- adnexal mass
- abdominal or pelvic tumor suspicious for ovarian cancer metastases (either suspected on clinical grounds, or known from prior tissue sampling)
- Female,
- Age \>= 18 years
- Creatinine \</= 1.5 mg/dL
- Ability to understand a written informed consent document, and the willingness to sign it
Exclusion
- Pregnant or breastfeeding women
- Patient unlikely to comply with study procedure, restrictions and requirements and judged by the investigator to be unsuitable for study participation.
Key Trial Info
Start Date :
April 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03857087
Start Date
April 2 2018
End Date
June 30 2022
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94115